Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
NCT06785012 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-89495120
Study Locations (20)
California
- CI Trials — Bellflower
- Wake Research PRI Encino — Encino
- National Institute Of Clinical Research — Garden Grove
- WR-Newport Beach — Newport Beach
- ATP Clinical Research — Orange
- Anderson Clinical Research — Redlands
- Artemis Institute for Clinical Research — San Diego
- Lumos Clinical Research Center LLC — San Jose
- Syrentis Clinical Research — Santa Ana
- Inland Psychiatric Medical Group Inc — Temecula
- Sunwise Clinical Research — Walnut Creek
Arizona
- Chandler Clinical Trials — Chandler
- IMA Clinical Research PC Phoenix — Phoenix
- Noble Clinical Research — Tucson
- University of Arizona — Tucson
Florida
- Gulfcoast Medical Research Center — Fort Myers
- The Medici Medical Research — Hollywood
- Advanced Research Institute of Miami — Homestead
Alabama
- UAB Huntsville Regional Medical Campus — Huntsville
Colorado
- Mountain View Clinical Research — Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2024-12-26 |
| Est. Completion | 2026-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06785012
The ClinicalTrials.gov registry entry for NCT06785012 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 442 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06785012 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Arizona, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06785012 about?
NCT06785012 is a clinical study titled "A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder". The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
What is the current status of trial NCT06785012?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2024-12-26. Estimated completion is 2026-06-26.
What conditions does trial NCT06785012 study?
This clinical trial studies the following conditions: Depressive Disorder, Major. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06785012?
The interventions under investigation include: Placebo (DRUG), JNJ-89495120 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06785012?
This trial is sponsored by Janssen Research & Development, which has 442 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06785012 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.